These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 24055064)

  • 21. Basic pharmacokinetics.
    Brock-Utne JG; Kingston HG
    S Afr Med J; 1980 Aug; 58(9):361-5. PubMed ID: 7404256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developmental Pharmacokinetics in Neonates: Maturational Changes and Beyond.
    Allegaert K; Mian P; van den Anker JN
    Curr Pharm Des; 2017; 23(38):5769-5778. PubMed ID: 28950819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical review of pharmacology concepts.
    Janda SM; Fagan NL
    Urol Nurs; 2010; 30(1):15-20. PubMed ID: 20359141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research.
    Tabata K; Hamakawa N; Sanoh S; Terashita S; Teramura T
    Eur J Drug Metab Pharmacokinet; 2009; 34(2):117-28. PubMed ID: 19645221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.
    Jones HM; Mayawala K; Poulin P
    AAPS J; 2013 Apr; 15(2):377-87. PubMed ID: 23269526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic concepts revisited--basic and applied.
    Patel K; Kirkpatrick CM
    Curr Pharm Biotechnol; 2011 Dec; 12(12):1983-90. PubMed ID: 21554220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Applications of human pharmacokinetic prediction in first-in-human dose estimation.
    Zou P; Yu Y; Zheng N; Yang Y; Paholak HJ; Yu LX; Sun D
    AAPS J; 2012 Jun; 14(2):262-81. PubMed ID: 22407287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. truPK -- human pharmacokinetic models for quantitative ADME prediction.
    Subramanian K
    Expert Opin Drug Metab Toxicol; 2005 Oct; 1(3):555-64. PubMed ID: 16863461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic parameters: which are necessary to define a drug substance?
    Benet LZ
    Eur J Respir Dis Suppl; 1984; 134():45-61. PubMed ID: 6586486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probe ADME and test hypotheses: a PATH beyond clearance in vitro-in vivo correlations in early drug discovery.
    Bell LC; Wang J
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1131-55. PubMed ID: 22681474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How Transporters Have Changed Basic Pharmacokinetic Understanding.
    Benet LZ; Bowman CM; Sodhi JK
    AAPS J; 2019 Sep; 21(6):103. PubMed ID: 31482335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug metabolism and pharmacokinetics in drug discovery.
    Roberts SA
    Curr Opin Drug Discov Devel; 2003 Jan; 6(1):66-80. PubMed ID: 12613278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integration of physicochemical and pharmacokinetic parameters in lead optimization: a physiological pharmacokinetic model based approach.
    Benjamin B; Barman TK; Chaira T; Paliwal JK
    Curr Drug Discov Technol; 2010 Sep; 7(3):143-53. PubMed ID: 20843296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.
    Rostami-Hodjegan A
    Clin Pharmacol Ther; 2012 Jul; 92(1):50-61. PubMed ID: 22644330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters.
    Smit C; De Hoogd S; Brüggemann RJM; Knibbe CAJ
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):275-285. PubMed ID: 29431542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primer on clinical pharmacokinetics.
    Bauer LA
    Am J Hosp Pharm; 1983 Oct; 40(10):1637-41. PubMed ID: 6638025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How drug-like are 'ugly' drugs: do drug-likeness metrics predict ADME behaviour in humans?
    Ritchie TJ; Macdonald SJ
    Drug Discov Today; 2014 Apr; 19(4):489-95. PubMed ID: 24462956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
    Lai Y; Varma M; Feng B; Stephens JC; Kimoto E; El-Kattan A; Ichikawa K; Kikkawa H; Ono C; Suzuki A; Suzuki M; Yamamoto Y; Tremaine L
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):723-43. PubMed ID: 22509796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest.
    Lees P; Landoni MF; Giraudel J; Toutain PL
    J Vet Pharmacol Ther; 2004 Dec; 27(6):479-90. PubMed ID: 15601442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.